NovaBridge Biosciences. (NBP) Income Statement (2017 - 2025)
Annual Income Statement report data from Dec 31, 2017 to Dec 31, 2025 for NovaBridge Biosciences. (NBP) in CNY with ability to convert in USD.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | - | - | 28M | -221.56M | 88M (-94.29%) | 1.54B (+5042.23%) | 30M (-44.22%) | 54M (+365.22%) | 12M |
Cost Of Revenue | - | - | - | 27M (-41.33%) | 46M | - | - | - | - |
Costof Goods And Services Sold | - | - | - | 27M (-41.33%) | 46M | - | - | - | - |
Gross Profit | - | - | - | -248.80M | 42M (-97.30%) | 1.54B (+5042.23%) | 30M | - | - |
Operating Expenses | |||||||||
Research And Development | - | - | 811M (-10.42%) | 905M (-25.40%) | 1.21B (+23.18%) | 985M (+17.17%) | 840M (+97.27%) | 426M (+59.51%) | 267M |
Selling General And Administrative | - | - | 453M (-44.47%) | 816M (-9.35%) | 900M (+123.64%) | 402M (-38.52%) | 655M (+885.92%) | 66M (+160.97%) | 25M |
Operating Expenses | 94M (+83.30%) | 51M (-29.21%) | 73M (+40.99%) | 52M (-97.56%) | 2.11B (+52.32%) | 1.39B (-7.22%) | 1.49B (+203.60%) | 492M (+68.34%) | 293M |
Depreciation And Amortization | - | - | 24M (-5.53%) | 25M (+83.33%) | 14M (+8.66%) | 13M (+29.59%) | 9.80M (+46.27%) | 6.70M (+318.75%) | 1.60M |
Operating Income | |||||||||
Operating Income | -94.27M (+83.30%) | -51.43M (-28.59%) | -72.02M (+35.68%) | -53.08M | - | - | - | - | - |
Ebit | -94.27M (+83.30%) | -51.43M (-28.59%) | -72.02M (+35.68%) | -53.08M (-97.73%) | -2.33B | 484M | -1.45B (+272.08%) | -389.42M (+33.09%) | -292.60M |
EBITDA | -88.34M (+297.39%) | -22.23M (-53.80%) | -48.12M (+73.22%) | -27.78M (-98.80%) | -2.32B | 497M | -1.44B (+276.03%) | -382.72M (+31.52%) | -291.00M |
Other Income / Expenses | |||||||||
Interest Income | - | - | 52M (+92.31%) | 27M (+26.16%) | 21M (-11.97%) | 24M (-20.74%) | 31M (+564.57%) | 4.60M (+434.88%) | 860K |
Interest Expense | - | - | 720K (+7100.00%) | 10K | - | 960K (-67.89%) | 2.99M (-74.44%) | 12M (+107.45%) | 5.64M |
Net Interest Income | - | - | 51M (+89.70%) | 27M (+26.11%) | 21M (-8.34%) | 23M (-15.63%) | 28M | -7.10M (+48.54%) | -4.78M |
Other Non Operating Income | - | - | -38.11M (-69.89%) | -126.59M | 83M (-79.86%) | 413M | -20.20M (+20.38%) | -16.78M | 1.53M |
Net Income | |||||||||
Income Before Tax | - | - | -1.47B (-41.53%) | -2.51B (+7.36%) | -2.33B | 483M | -1.45B (+261.98%) | -401.11M (+34.49%) | -298.24M |
Income Tax Expense | - | - | - | 700K | -3.15M | 12M | - | 1.72M | - |
Net Income From Continuing Operations | -88.34M (+297.39%) | -22.23M (-98.48%) | -1.47B (-41.54%) | -2.51B (+7.54%) | -2.33B | 471M | -1.45B (+260.44%) | -402.83M (+35.07%) | -298.24M |
Net Income | -88.34M (+297.39%) | -22.23M (-98.48%) | -1.47B (-41.54%) | -2.51B (+7.54%) | -2.33B | 471M | -1.45B (+260.44%) | -402.83M (+35.07%) | -298.24M |
Comprehensive Income Net Of Tax | -80.18M (+180.15%) | -28.62M (-97.93%) | -1.38B (-34.45%) | -2.11B (-14.60%) | -2.47B | 350M | -1.44B (+312.79%) | -349.14M (+19.44%) | -292.32M |